JP2021522786A5 - - Google Patents
Info
- Publication number
- JP2021522786A5 JP2021522786A5 JP2020560958A JP2020560958A JP2021522786A5 JP 2021522786 A5 JP2021522786 A5 JP 2021522786A5 JP 2020560958 A JP2020560958 A JP 2020560958A JP 2020560958 A JP2020560958 A JP 2020560958A JP 2021522786 A5 JP2021522786 A5 JP 2021522786A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- structural unit
- subunit
- linker segment
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025082038A JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810420739.6 | 2018-05-04 | ||
| CN201810420739.6A CN110437339B (zh) | 2018-05-04 | 2018-05-04 | 一种以白介素15为活性成分的融合蛋白型药物前体 |
| PCT/US2019/030594 WO2019213517A1 (en) | 2018-05-04 | 2019-05-03 | Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025082038A Division JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522786A JP2021522786A (ja) | 2021-09-02 |
| JP2021522786A5 true JP2021522786A5 (enExample) | 2022-05-13 |
| JP7684047B2 JP7684047B2 (ja) | 2025-05-27 |
Family
ID=68386875
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560958A Active JP7684047B2 (ja) | 2018-05-04 | 2019-05-03 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
| JP2025082038A Pending JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025082038A Pending JP2025124695A (ja) | 2018-05-04 | 2025-05-15 | インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12441781B2 (enExample) |
| EP (1) | EP3788068A4 (enExample) |
| JP (2) | JP7684047B2 (enExample) |
| KR (1) | KR20210028150A (enExample) |
| CN (4) | CN110437339B (enExample) |
| AU (1) | AU2019262590B2 (enExample) |
| CA (1) | CA3099039A1 (enExample) |
| WO (1) | WO2019213517A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| CN111100211B (zh) * | 2019-01-30 | 2022-04-08 | 武汉九州钰民医药科技有限公司 | 一种Fc融合蛋白及其应用 |
| MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
| US20220402988A1 (en) * | 2019-12-05 | 2022-12-22 | Immune Targeting Inc. | Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof |
| CN113135996A (zh) * | 2019-12-09 | 2021-07-20 | 启愈生物技术(上海)有限公司 | 一种双特异抗体及其应用 |
| CN115151279B (zh) * | 2019-12-13 | 2026-05-05 | 科优基因公司 | 基于细胞因子的可生物活化药物及其使用方法 |
| WO2021131944A1 (ja) * | 2019-12-27 | 2021-07-01 | 国立大学法人神戸大学 | 癌遺伝子治療薬 |
| WO2021142476A1 (en) * | 2020-01-12 | 2021-07-15 | Dragonfly Therapeutics, Inc. | Single-chain polypeptides |
| CN113321738A (zh) * | 2020-02-27 | 2021-08-31 | 启愈生物技术(上海)有限公司 | 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用 |
| US20230141575A1 (en) * | 2020-03-18 | 2023-05-11 | City Of Hope | Multivalent chemokine receptor binding complexes |
| US20230226203A1 (en) * | 2020-06-18 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| CN114057889B (zh) * | 2020-07-30 | 2023-11-10 | 深圳市北科生物科技有限公司 | 二硫键稳定的IL15-IL15Rα复合物及其应用 |
| JP2023540296A (ja) * | 2020-08-31 | 2023-09-22 | ジーアイ・セル・インコーポレイテッド | ＩＬ１５タンパク質、ＩＬ１５受容体アルファタンパク質、Ｆｃドメイン及びＩＬ２タンパク質を含む融合タンパク質並びにその用途 |
| JP2023540629A (ja) * | 2020-09-16 | 2023-09-25 | ベイジーン リミテッド | インターロイキン１５構築物及び使用方法 |
| CN114380919B (zh) * | 2020-10-18 | 2024-06-25 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| CN113321736B (zh) * | 2020-12-30 | 2024-01-09 | 苏州复融生物技术有限公司 | 一种长效化白介素15融合蛋白及其制备方法和应用 |
| JP2024515591A (ja) * | 2021-04-08 | 2024-04-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｃｒに結合する多機能性分子およびその使用 |
| CN113321740B (zh) * | 2021-05-08 | 2023-07-18 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| CN113817072B (zh) * | 2021-10-28 | 2024-02-20 | 苏州生物医药转化工程中心 | 一种白细胞介素15及其受体-单克隆抗体融合蛋白的纯化贮存方法 |
| JP2024539432A (ja) * | 2021-11-15 | 2024-10-28 | 中国科学院生物物理研究所 | インターロイキン１５を有効成分とする融合タンパク質構築物およびその使用 |
| WO2023160721A1 (en) * | 2022-02-28 | 2023-08-31 | Wuxi Biologics (Shanghai) Co., Ltd. | Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof |
| KR20250058784A (ko) * | 2022-08-05 | 2025-04-30 | 스테이드슨 바이오팔마 아이엔씨. | 마스킹 폴리펩티드, 활성화 가능한 신규의 프로드럭 및 이의 사용 방법 |
| EP4562059A1 (en) * | 2023-02-21 | 2025-06-04 | RemeGen Co., Ltd. | Il-15 agonists for cancer |
| WO2024230591A1 (zh) * | 2023-05-06 | 2024-11-14 | 北京新合睿恩生物医疗科技有限公司 | IL-15融合蛋白及其mRNA序列和应用 |
| CN116554356B (zh) * | 2023-05-16 | 2024-01-23 | 武汉大学 | 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用 |
| WO2025129454A1 (zh) * | 2023-12-19 | 2025-06-26 | 中国科学院生物物理研究所 | Il-15与t细胞共刺激分子抗体构成的双功能融合蛋白 |
| WO2026006679A1 (en) * | 2024-06-28 | 2026-01-02 | The Regents Of The University Of California | Retroviral vectors |
| WO2026037415A1 (zh) * | 2024-08-16 | 2026-02-19 | 北京清辉联诺生物科技有限责任公司 | 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用 |
| CN121949562A (zh) * | 2024-10-30 | 2026-05-01 | 钱杭江医药科技(嘉兴)有限公司 | 一种新型蛋白复合物的二聚体化合物及其制备方法和制药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2007126553A (ru) | 2004-12-13 | 2009-01-20 | Цитос Биотехнологи Аг (Ch) | Упорядоченные ряды антигенов ил-15 и их применение |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2619229B1 (en) * | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| EP2915569A1 (en) * | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| LT3235830T (lt) * | 2014-12-19 | 2020-12-28 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukino 15 baltymų kompleksas ir jo naudojimas |
| CN112574316A (zh) * | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| AU2016326575A1 (en) * | 2015-09-25 | 2018-04-12 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
| JP6936221B2 (ja) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| BR112019007281A2 (pt) * | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
-
2018
- 2018-05-04 CN CN201810420739.6A patent/CN110437339B/zh active Active
-
2019
- 2019-05-03 CN CN202510533066.5A patent/CN120463816A/zh active Pending
- 2019-05-03 CN CN201980045118.7A patent/CN112585161B/zh active Active
- 2019-05-03 KR KR1020207034734A patent/KR20210028150A/ko active Pending
- 2019-05-03 CN CN202510533077.3A patent/CN120463817A/zh active Pending
- 2019-05-03 CA CA3099039A patent/CA3099039A1/en active Pending
- 2019-05-03 AU AU2019262590A patent/AU2019262590B2/en active Active
- 2019-05-03 JP JP2020560958A patent/JP7684047B2/ja active Active
- 2019-05-03 EP EP19796151.9A patent/EP3788068A4/en active Pending
- 2019-05-03 WO PCT/US2019/030594 patent/WO2019213517A1/en not_active Ceased
- 2019-05-03 US US17/051,160 patent/US12441781B2/en active Active
-
2025
- 2025-05-15 JP JP2025082038A patent/JP2025124695A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025032113A5 (enExample) | ||
| JP2021521822A5 (enExample) | ||
| EP3844181B1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| US12624088B2 (en) | Chimeric receptor comprising a ligand binding domain and an endodomain comprising a cytokine receptor endodomain and an intracellular T cell signalling domain | |
| EP3844182B1 (en) | Single-chain and multi-chain chimeric polypeptides and uses thereof | |
| Wilkie et al. | Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling | |
| CN110724200B (zh) | 嵌合细胞因子受体 | |
| JP2022169543A (ja) | 改善された養子ｔ細胞療法 | |
| ES3018558T3 (es) | Célula T que expresa un receptor de célula T gamma-delta (TCR) y un receptor de antígeno quimérico (CAR) | |
| AU2020294797B2 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| CN111527109A (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2023503868A5 (enExample) | ||
| Karches et al. | Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy | |
| Kermer et al. | An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site | |
| JP2023518434A (ja) | インターロイキン２変異体およびその使用 | |
| WO2017000913A1 (zh) | 用于肿瘤靶向治疗的白细胞介素15融合蛋白 | |
| WO2021032116A1 (zh) | 一种免疫细胞因子及其制备与用途 | |
| JP2023551481A5 (enExample) | ||
| CN112601546A (zh) | Plap-car-效应细胞 | |
| Lo et al. | Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor | |
| CN110903402A (zh) | 一种双特异性融合蛋白及其构建方法与应用 | |
| JP2023540022A5 (enExample) | ||
| JP2023540023A5 (enExample) | ||
| Burckhart et al. | Tumor-specific crosslinking of GITR as costimulation for immunotherapy | |
| CN114585377A (zh) | 表达嵌合蛋白的t细胞 |